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Abstract
BACKGROUND: Radioiodine therapy (RIT) in patients with large nontoxic multinodular goiter (MNG) recently becomes more 
common method in comparison to surgery (especially in elderly patients and with contraindications because of severe chronic 
diseases other systems). Repeatedly low thyroid radioactive iodine uptake (RAIU) decreases effectiveness of RIT or makes it 
impossible. The recombinant human thyrotropin can increase RAIU and improve the results of RIT. 
The aim of the study was to assess the influence of a single very low dose (0.03 mg) of rhTSH on RAIU and thyroid function 
in euthyroid (MNG-EU) and subclinical hyperthyroid (MNG-SC) patients with a large multinodular goiter.
MATERIAL AND METHODS: 40 patients (14 male, 26 female, age 57–80 yr) with large non-toxic MNG over 80 grams and with 
baseline RAIU < 40% were included into the double-blind randomized study and divided into two groups: rhTSH-group and 
control group. First group received the single intramuscular injection of 0.03 mg rhTSH and the second received placebo. The 
RAIU were measured 24 and 48 hours after the rhTSH and then all the patients were administered therapeutic doses of I-131. TSH 
and free thyroxine levels were measured at 1st and 2nd day after the injection of rhTSH and later, at 4 and 8 weeks after the RIT. 
RESULTS: The mean RAIU increased significantly from 30.44 ± 7.4% to 77.22 ± 8.7% (p < 0.001). There were no statistically 
significant differences in RAIU between euthyroid (MNG-EU) and subclinically hyperthyroid (MNG-SC) patients. The peak of 
serum TSH was noticed 24 hours after rhTSH injection and in MNG-EU patients it has remained within normal range, similarly 
as fT4. In the MNG-SC group the administration of rhTSH resulted in a significant increase in the TSH values after 24 hours, 
whose mean level slightly exceeded the upper limit of the normal range with normalization at 48 hours. 8 weeks after the RIT, 
the TSH and fT4 levels did not exceed the normal range and did not differ in a statistically significant way.
Conclusions: Even the single very low dose of rhTSH increases the values of RAIU in significant way, in euthyroid and sub-
clinically hyperthyroid patients. The administration of rhTSH is well-tolerated. Neoadjuvant administration of a low dose (0.03 
mg) of rhTSH before I-131 seems to be an optimal method of management which may increase the effectiveness of RIT and 
decrease the exposure of the patients to absorbed doses of ionizing radiation.
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Background
Radioactive iodine (I-131) therapy (RIT) has been a signifi-
cant part of the treatment of benign thyroid disorders for over 70 
years [1]. The main indication for the use of I-131 is hyperthyroidism 
in the case of adenoma (nodular goiter), multinodular goiter (MNG) 
and Graves’ disease (GD). In nodular goiter, oral administration of 
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antithyroid drugs (ATD) is aimed only at appropriate preparation of 
the patients for RIT, which is performed when malignant lesions have 
been ruled out. The efficacy of RIT in these cases depends on 
the patient’s condition as well as on appropriate preparation for 
treatment [1–3].
In GD, RIT is a second-line method of treatment, preferred in 
the case of ineffective antithyroid therapy or disease recurrence. 
Taking into consideration the immunosuppressive effects of ATD, 
the administration lasting at least 1.5 years is associated with 
an approx. 50% probability of achieving long-term remission [1, 4].
RIT has been increasingly often used in the treatment of pa-
tients with MNG (Figure 1). Since I-131 was first used in order to 
reduce thyroid volume approx. 20 years ago, RIT has been grow-
ing in popularity and becoming an attractive alternative to surgical 
treatment [1, 5–8]. Advanced age and concomitant diseases, such 
as arrhythmia or circulatory failure, may hinder general anesthesia 
or constitute a contraindication for thyroidectomy. Due to the fear 
of undesirable consequences of surgery, many patients do not 
consent to this type of treatment [8, 9].
Until recently, the administration of L-thyroxine was another con-
servative method of treatment aimed at reducing the size of the goiter 
(especially small-sized goiter). Due to the low effectiveness, the lack 
of permanent effects of the therapy and the presence of adverse 
effects (e.g. cardiac arrhythmia and osteopenia), it is not currently 
considered to be a standard method of goiter treatment [1, 9].
The occurrence and development of symptoms associated with 
thyroid enlargement takes place over a long period of time as the 
goiter grows gradually, usually at a rate of 0–20% per year. At the 
early stage of the disease, the patients usually feel well and do not 
report any problems with their general well-being. As the thyroid 
increases in volume, local symptoms develop, including the sensa-
tion of compression in the neck area, difficulty swallowing, dyspnea 
associated with tracheal deviation and compression. Cough or 
hoarseness, associated with the compression of the thyroid tissue 
on the recurrent laryngeal nerve, are less frequent. In the case of 
untreated goiter, the probability of hyperthyreosis increases by 10% 
every five years; hyperthyreosis leads to the development of numer-
ous symptoms associated with other organs and systems [1, 9–11].
Treatment with the use of I-131 leads to a decrease in the goiter 
volume. Consequently, the compression is eliminated or signifi-
cantly reduced. This method is non-invasive and well-tolerated by 
the patients [10].
However, large goiters, especially in patients over the age of 60, 
may be accompanied by low iodine uptake of the tissue (RAIU) and 
heterogeneous radioisotope uptake, which has a negative influence 
on the effectiveness of RIT and results in the need for repeated use 
of I-131. In such cases, the duration of RIT is extended and the 
dose of radiation absorbed by the body increases [5, 9, 11, 12].
Recombinant human thyrotropin (rhTSH) is used at a dose of 
2 x 0.9 mg in the adjuvant therapy of various thyroid cancers after 
thyroidectomy. Exogenous thyrotropin increases the iodine uptake 
in the remains of thyroid tissue and possible distant metastases, 
allowing for radioactive iodine therapy [13, 14].
There have been reports on the positive influence of rhTSH on 
the outcomes of RIT in large non-toxic MNG through increasing 
RAIU and improving the homogeneity of I-131 uptake. Even very 
low doses of exogenous thyrotropin stimulate thyroid cells and may 
cause a significant increase in RAIU, thus improving the effective-
ness of RIT. Consequently, the use of the first therapeutic dose of 
I-131 might allow for the reduction of the volume of nodules with 
a good uptake of the isotope as well as the surrounding overgrown 
thyroid tissue. However, excessive activation of the remaining thy-
roid tissue may result in the stimulation of hormone production and 
release, thus inducing hyperthyroidism and leading to the occur-
rence of a number of symptoms. So far, a dose of rhTSH effective 
before RIT and safe in patients with a preserved enlarged thyroid 
has not been determined [15–17].
The aim of the study was to assess the influence of a sin-
gle very low dose (0.03 mg) of rhTSH on the iodine uptake and 
homogeneity of the thyroid uptake of I-131 as well as the thyroid 
metabolic state in euthyroid (MNG-EU) and subclinical hyperthyroid 
(MNG-SC) patients with a large nodular goiter.
Material and methods
After obtaining the approval of the Bioethics Committee 
and written consents of the patients, we started a prospective 
double-blind randomized study involving 40 subjects. The study 
enrolled patients who sought medical advice at the Nuclear Medi-
cine Department and met the criteria of the study, according to the 
order in which they had presented to the clinic. The inclusion criteria 
were: the presence of non-toxic MNG over 80 ml in volume and RAIU 
not exceeding 40% at 24 hours after the administration of I-131.
During the first qualification visit, the patients underwent 
history-taking and physical examination. Considerable importance 
was placed on the presence and severity of the symptoms, such 
as compression signs, difficulty swallowing, dyspnea on exertion/at 
rest, cough, hoarseness. The patients with paroxysmal atrial fibril-
lation or other severe forms of cardiac arrhythmia and those with 
chronic obstructive pulmonary disease or asthma were excluded 
from the study. Pregnancy was ruled out in the women of childbear-
ing age. In order to assess the thyroid metabolic state with radio-
metric methods, the levels of TSH and free thyroid hormones in the 
serum were measured. T3-toxicosis and concomitant autoimmune 
thyroid diseases were ruled out through the determination of thyroid 
peroxidase antibodies and TSH receptor antibodies.
The assessment of goiter volume was based on a thyroid 
ultrasound where the total volume of the gland is the sum of the 
Figure 1. Large MNG (H.M., 71 years old — author’s collections)
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volumes of both lobes, calculated with the use of the following 
formula: lobe volume = length x width x depth x 0.5. The data 
obtained during the ultrasound also provided indirect information 
concerning the structure and type of the nodules. Chest radiography 
allowed for the assessment of possible deviation or the degree of 
compression of the trachea. The patients in whom the width of the 
trachea (in its narrowest part) was less than 0.5 cm were excluded 
from the study.
Each patient underwent thyroid scintigraphy with the assessment 
of the I-131 distribution and RAIU 24 and 48 hours after the oral ad-
ministration of an I-131 diagnostic capsule with an activity of 2 MBq. 
Only patients with RAIU less than 40% were included in the study.
The study group consisting of 40 patients was randomly di-
vided into two groups of 20 patients each, i.e. a control group and 
rhTSH-group (Table 1).
Patients from both groups received intramuscular injections in 
equal volume (1 cm3 each). In the control group, the injections con-
tained physiological saline (0.9%) while the patients from the 
rhTSH-group received a solution of 0.03 mg of rhTSH in physi-
ological saline. The study used recombinant human thyrotropin in 
the form of Thyrogen (by Genzyme).
Immediately after the injections, both groups again received 
diagnostic doses of I-131 and underwent another thyroid scintig-
raphy with the assessment of iodine uptake at 24 and 48 hours.
Next, 48 hours after the administration of rhTSH/placebo, all 
patients received orally capsules with I-131 with an appropriate 
therapeutic activity whose value had been calculated on the ba-
sis of Marinelli’s formula [18], taking into consideration new RAIU 
values (and the absorbed dose of 180 Gy [1]). Prior to radioac-
tive iodine therapy, the patients underwent obligatory fine needle 
biopsy of the focal lesions, conducted according to the accepted 
standards, namely the Polish Recommendations of 2010, based on 
the standards of the American and European Thyroid Association.
The administered activity of I-131 could not exceed 800 MBq 
as this is the maximum activity approved for outpatient treatment in 
Poland. The mean therapeutic activity of I-131 was 715.79 ± 101.45 
MBq in the rhTSH-group and 768.42 ± 74.93 MBq in the control 
group. The therapeutic doses of I-131 used in both groups did not 
differ in a statistically significant way.
All patients were further followed up. Follow-up visits at 4 and 
8 weeks after the administration of radioactive iodine consisted 
of a physical examination, history-taking and the measurement of 
TSH and fT4 levels.
The normality of distribution was assessed by the Shapiro-Wilk 
W-test. Two groups with normal distribution were compared with 
Student’s t-test and a test for two variances. The significance level 
was set at a = 0.05.
The data presented in the present paper are preliminary results of 
the study in which observations and examinations of patients will 
be continued for over a year. The study also involves a comparison 
of the effectiveness of RIT in patients from the rhTSH and control 
groups through the assessment of the degree of goiter reduction 
based on the data from history and physical examination and 
most importantly on the results of the following imaging studies: 
ultrasound at 6, 12 and 18 months and iodine thyroid scintigraphy 
at 12 months after the treatment.
Results
After intramuscular injections of 0.03 mg of rhTSH and a repeat 
thyroid scintigraphy, the RAIU increased very significantly (over two 
times) from 30.44 ± 7.4% to 77.22 ± 8.7% (p < 0.001) (Figure 2). 
The differences between the mean RAIU before and after the ad-
ministration of rhTSH were 49.2 ± 6.7% in the MNG-SC group and 
44.4 ± 9.5% in the MNG-EU group and did not vary in a statistically 
significant way (p = 0.21) (Table 2, Figure 3).
Table 1. Characteristics of the rhTSH-group and control group
Total rhTSH-group control group p
No. of patients 40 20 20
Female 26 12 14
Male 14 8 6
Mean age (years) 65 65 65
MNG-EU No. of patients 22 10 12
Mean level of TSH [uIU/ml] 0.45 ± 0.2 0.48 ± 0.2 0.43 ± 0.2 0.681
Mean level of fT4 [pmol/l] 18.2 ± 1.6 18.3 ± 1.9 18.5 ± 1.3 0.832
MNG-SC No. of patients 18 10 8
Mean level of TSH [uIU/ml] 0.08 ± 0.06 0.07 ± 0.07 0.09 ± 0.06 0.799
Mean level of fT4 [pmol/l] 19.6 ± 1.6 19.5 ± 2.2 19.2 ± 1.2 0.712
Figure 2. Thyroid uptake of I-131 (RAIU) in the rhTSH-group before 
and after rhTSH administration
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In the control group, the mean RAIU was 29.4 ± 7.5% at 
baseline; after placebo administration, it slightly changed and 
was 30.2 ± 7.8% (ns).
In the rhTSH-group, the level of serum TSH increased fol-
lowing the administration of exogenous thyrotropin and peaked 
at 24 hours after the rhTSH injection. In patients who had been 
in the euthyroid state at baseline, mean THS values at 24 and 
48 hours after rhTSH administration did not exceed the upper limit 
of the normal range, i.e. 4.5 uIU/ml (Table 3).
In the MNG-SC group, with a decreased mean TSH level of 
0.07 uIU/ml at baseline, the administration of an analogous dose 
of rhTSH resulted in a significant increase in the TSH values, 
whose mean level slightly exceeded the upper limit of the range 
considered normal and was 4.97 uIU/ml at 24 hours, undergoing 
normalization at 48 hours after the administration of thyrotropin. 
Despite the significant increase in TSH levels in the patients with 
subclinical hyperthyroidism at baseline, mean thyrotropin levels at 
24 hours after rhTSH administration in the MNG-EU and MNG-SC 
groups did not differ in a statistically significant way. In the con-
trol group (both MNG-EU and MNG-SC) the mean serum TSH 
levels were comparable before and at 24 and 48 hours after the 
administration of physiological saline (Table 3, Figure 4).
Four weeks after RIT, laboratory tests performed during the first 
follow-up visit showed a temporary decrease in thyrotropin levels in 
all patients. Mean TSH values in the MNG-SC patients (from both 
the control and rhTSH-group) were below the lower limit of the 
normal range, reaching 0.03 and 0.04 uIU/ml, respectively, while 
Table 2. Comparison of RAIU in patients with MNG-SC and MNG-EU 
— rhTSH-group
rhTSH-group MNG-SC MNG-EU p
RAIU before rhTSH (%) 29.5 ± 8.4 31.4 ± 6.4 0.586
RAIU after rhTSH (%) 78.7 ± 8.7 75.8 ± 8.8 0.524
p < 0.001 < 0.001
Figure 3. Examples of thyroid scintigraphy images obtained 24 hours after the administration of I-131 with an activity of 2 MBq. A. Before rhTSH 
administration; B. 24 hours after rhTSH administration
Table 3. Comparison of mean values of TSH in patients from the rhTSH-group (MNG-SC vs. MNG-EU)
Serum TSH (uIU/ml)
Before  
rhTSH/placebo
24 h after  
rhTSH/placebo
48 h after  
rhTSH/placebo
4 weeks after  
rhTSH/placebo
8 weeks after  
rhTSH/placebo
rhTSH-group MNG-SC 0.07 4.97 1.88 0.04 0.2
MNG-EU 0.48 4.16 2.09 0.4 0.68
P p = 0.09 p = 0.048 ns p = 0.006 p = 0.012
A B
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the MNG-EU patients showed values lower as compared with 
the baseline levels, but within the normal range. During the next 
follow-up visit, at 8 weeks after RIT, the mean levels of serum TSH 
were comparable between the groups (rhTSH- and control group), 
with no statistically significant differences (Table 4, Figure 5).
Elevated TSH levels stimulate the release of fT4 and may result 
in a worse general condition of the patients. Consequently, the 
assessment of serum fT4 levels in patients after rhTSH admini-
stration was important. As early as at 24 hours after the injection 
of recombinant thyrotropin, the level of free thyrotropin increased, 
exceeding the limit of normal values, but fT4 levels exceeded the 
upper limit of the normal range only slightly. In the MNG-SC group, 
the mean level of free thyroxine was 23.67 pmol/ml and did not differ 
in a statistically significant way from the mean values obtained in the 
MNG-EU group (22.53 pmol/ml; normal range 0.2–22.5 pmol/ml). In 
the group of patients with subclinical hyperthyroidism at baseline, 
overt hyperthyroidism was observed also at 48 hours after rhTSH 
administration, while in the subjects who had been in the euthyroid 
state at baseline this indicator was normalized (Table 5, Figure 6).
In the control group (both MNG-EU and MNG-SC) the mean 
serum fT4 levels were comparable before and at 24 and 48 hours af-
ter the administration of physiological saline (Table 6, Figure 7).
After the administration of therapeutic I-131 doses in all patient 
groups, the fT4 levels determined during the follow-up visits at 
4 and 8 weeks did not exceed the normal range and did not differ 
in a statistically significant way (Table 6, Figure 7).
The patients underwent physical examination and history-taking 
before each assessment of the hormone levels. Physical examination 
did not show worsening of the patients’ state. The patients did not 
report intensified local symptoms or worrying clinical signs accompa-
nying the temporary increase in free thyroid hormone levels. Regular 
heart rate of < 100 beats per minute was found in all patients, including 
those with temporary overt hyperthyroidism. None of the followed-up 
patients were advised to take additional drugs, including beta-blockers.
Discussion
Despite the fact that RIT has been used in the treatment of 
thyroid diseases for over 70 years, some authors still consider it 
to be an unreliable method producing no satisfying results in the 
case of non-toxic nodular goiter [5, 6, 19, 20]. First reports on 
Figure 4. Comparison of mean values of serum TSH in MNG-SC 
and MNG-EU patients from the rhTSH-group (1. before rhTSH 
administration, 2. 24 hours after rhTSH administration, 3. 48 hours 
after rhTSH administration, 4. 4 weeks after rhTSH administration,  
5. 8 weeks after rhTSH administration)
Table 4. Comparison of mean values of TSH in patients from the rhTSH-group and control group
Serum TSH [uIU/ml]
Before 
rhTSH/placebo
24 h after  
rhTSH/placebo
48 h after  
rhTSH/placebo
4 weeks after  
rhTSH/placebo
8 weeks after  
rhTSH/placebo
MNG-SC rhTSH-group 0.07 4.97 1.88 0.04 0.2
control group 0.08 0.09 0.08 0.02 0.35
p ns p = 0.000 p = 0.009 ns ns
MNG-EU rhTSH-group 0.48 4.16 2.09 0.4 0.68
control group 0.43 0.45 0.44 0.21 0.5
p ns p = 0.012 p = 0.024 ns ns
Figure 5. Comparison of mean values of serum TSH in patients from the rhTSH-group and control group (1. before rhTSH administration,  
2. 24 hours after rhTSH administration, 3. 48h after rhTSH administration, 4. 4 weeks after rhTSH administration, 5. 8 weeks after rhTSH 
administration). A. MNG-SC; B. MNG-EU
A B
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non-invasive attempts at reducing goiter volume with I-131 were 
published at the beginning of the 1990s [21, 22]. They suggested 
the possibility of treating older patients with multiple systemic di-
seases who were disqualified from invasive treatment. Since then 
RIT of non-toxic goiter appears to have been growing in popular-
ity. However, a questionnaire conducted among the members of 
the American Thyroid Association and concerning the preferred 
methods of treatment of non-toxic goiter > 50 g in size showed 
that only 1% of the specialists chose RIT as a first-line method of 
treatment [6]. The members of the European Thyroid Association 
gave similar answers. However, in the Latin American countries the 
percentage was 7% [19]. Publications describe promising out-
comes achieved after the use of radioactive iodine in the treatment 
of euthyroid goiter. The degree of reduction in the volume of the 
goiter varies from 30% to 60% in different centers and depends on 
the characteristics of the study group, particularly on the size of 
the goiter. The smaller the goiter, the easier it is to achieve a larger 
Table 5. Comparison of mean values of fT4 in patients from the rhTSH-group (MNG-SC vs. MNG-EU)
Serum fT4 [pmol/ml]
Before  
rhTSH/placebo
24 h after 
 rhTSH/placebo
48 h after  
rhTSH/placebo
4 weeks after  
rhTSH/placebo
8 weeks after  
rhTSH/placebo
rhTSH-group MNG-SC 19.53 23.67 24.2 18.5 18.6
MNG-EU 18.33 22.53 21.55 19.1 19.8
P ns ns p = 0.032 ns ns
Figure 6. Comparison of mean values of serum fT4 in MNG-SC 
and MNG-EU patients from the rhTSH-group (1. before rhTSH 
administration, 2. 24 hours after rhTSH administration, 3. 48 h after 
rhTSH administration, 4. 4 weeks after rhTSH administration,  
5. 8 weeks after rhTSH administration)
Table 6. Comparison of mean values of fT4 in patients from the rhTSH-group and control group
Serum fT4 [pmol/l]
Before  
rhTSH/placebo 
24 h after  
rhTSH/placebo 
48 h after  
rhTSH/placebo 
4 weeks after  
rhTSH/placebo 
8 weeks after  
rhTSH/placebo 
MNG-SC rhTSH-group 19.53 23.67 24.2 18.5 18.6
control group 19.21 19.81 19.54 22.65 21.45
p ns p = 0.039 p = 0.031 ns ns
MNG-EU rhTSH-group 18.33 22.53 21.55 19.1 19.8
control group 18.49 18.23 18.45 21.65 19.44
p ns p = 0.048 p = 0.049 ns ns
Figure 7. Comparison of mean values of serum fT4 in patients from the rhTSH-group and control group (1. before rhTSH administration,  
2. 24 hours after rhTSH administration, 3. 48 hours after rhTSH administration, 4. 4 weeks after rhTSH administration, 5. 8 weeks after rhTSH 
administration). A. MNG-SC; B. MNG- EU
A B
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reduction in its volume even at low doses of I-131 [5, 19, 22, 23]. 
This results in considerably better effectiveness of the therapy 
as compared with conservative treatment with LT4 (and a lower 
risk of adverse effects as compared with conservative treatment). 
As societies age, the number of elderly patients with concomitant 
diseases affecting e.g. the circulatory and respiratory systems, 
in whom surgical treatment of non-toxic goiter is not performed, 
is constantly growing. Nevertheless, the occurrence of local symp-
toms caused by an enlarged thyroid requires the treatment, not just 
conducting observations [5]. The use of LT4 is impossible due to 
comorbidities and the administration of I-131 becomes a method 
of choice. Thyroid scintigraphy in patients over the age of 60 of-
ten shows low RAIU values accompanying large goiters [15, 17, 
24–26]. Consequently, a single administration of a maximum dose 
usually does not result in the desired outcomes and the treatment 
requires the administration of consecutive doses of I-131, which 
prolongs the duration of the therapy and has a negative influence 
on the satisfaction with the treatment. Moreover, the irradiation of 
the body increases. This is why factors which could safely improve 
the effectiveness of RIT are constantly sought [27]. Thyrotropin 
is a hormone which has a positive effect on iodine uptake and 
radiosensitivity of thyroid tissue [28]. Increased levels of TSH also 
improve the homogeneity of I-131 uptake in a multinodular goiter. 
Descriptions of first attempts at using recombinant human thyro-
tropin as an adjunct in radioactive iodine therapy of MNG can be 
found in the literature. However, the study groups described are 
very heterogeneous in terms of numerous significant factors influ-
encing the course and results of the treatment, such as the size 
of the goiter, iodine uptake of the thyroid tissue, thyroid metabolic 
state, and particularly the patterns of patient preparation and rhTSH 
administration. Many of the studies were not randomized and had 
no control groups and the majority of the publications described 
study groups consisting of no more than 20 patients.
Nevertheless, according to the above-mentioned paper [6], 
when selecting I-131 for the treatment of non-toxic MNG more 
than 50% of the respondents suggested the wish to use rhTSH 
as neoadjuvant therapy.
Human thyrotropin is routinely used as an adjunct to the treat-
ment of differentiated thyroid cancer in the form of two 0.9 mg injec-
tions. A dose of 2 x 0.9 mg is considered safe and does not result 
in adverse effects such as hyperthyroidism as the patients have 
had their thyroid glands surgically removed [29]. The administra-
tion of exogenous thyrotropin in a patient with preserved thyroid 
whose size considerably exceeds the normal range may result in 
the induction of hyperthyreosis, which has a negative impact on the 
patient’s condition, particularly in the case of elderly patients with 
numerous comorbidities. There is no consensus as to the dose 
of rhTSH used before the administration of I-131. The studies de-
scribed so far have used doses from 0.005 mg to 0.9 mg. The 
injections have been performed once, 2–24 hours before the ad-
ministration of I-131, or twice, at an interval of 24 hours [26, 30–34].
In our study, after the use of a single low dose of rhTSH 
(0.03 mg) the 24-hour RAIU increased by 144% in the MNG-EU 
group and by 166% in the patients with MNG-SC. There were no 
significant differences in iodine uptake before and after the admini-
stration of thyrotropin between the patients in the euthyroid and 
subclinical hyperthyroid state. One report described a significant 
increase in RAIU (by 87%) after the administration of a very low 
dose of rhTSH (0.01 mg) and the use of a 3 times higher rhTSH 
dose (0.03 mg) resulted in further stimulation of RAIU (by 145% 
as compared with the baseline values) [35]. Other authors observed 
RAIU increasing by 40–91% after the administration of 0.03 mg of 
exogenous thyrotropin [24, 25]. Romao et al. administered 0.1 mg 
of rhTSH and achieved a 111% increase in RAIU. The degree of 
stimulation of RAIU in this study was lower than in our case. After 
intramuscular administration of 0.1 mg of rhTSH performed twice 
(over two consecutive days) the mean RAIU increased from the 
baseline 35% only to 45% [36]. Only Albino et al. found a signifi-
cantly higher (as compared with other studies) increase in RAIU 
as it grew 4.5 times after 0.1 mg of thyrotropin was administered 
twice [30]. In other papers, authors suggested the use of 0.45 mg 
of rhTSH, achieving a 151% increase in iodine uptake [37]. Torres et 
al. injected 0.9 mg of exogenous thyrotropin and found only a 75% 
increase in the 24-hour I-131 uptake; however, this study was con-
ducted in healthy volunteers and should not be compared with the 
outcomes obtained in MNG patients [38]. RAIU values achieved 
after the administration of various doses of exogenous thyrotropin 
allow for conclusions regarding a threshold value of the dose of 
rhTSH above which there is no further significant increase in iodine 
uptake. Moreover, no significant differences were found in the va-
lues of uptake in MNG patients after the administration of 0.1 mg 
as compared with 0.3 mg of rhTSH [33]. In addition, scintigraphy 
performed 24 hours after the administration of rhTSH shows im-
proved homogeneity of uptake, which partially translates to the 
above-mentioned RAIU increase [25, 39]. Increased iodine uptake 
not only in the nodules with a good uptake of the isotope, but also 
in the extranodular tissue or nodules whose previous I-131 uptake 
was low may result in a higher degree of goiter volume reduction 
after the use of radioiodine in therapeutic activities [35, 40]. Our 
results and previous reports do not indicate the necessity of using 
an rhTSH dose higher than 0.03 mg in order to achieve a signifi-
cant increase in RAIU. A single low dose of 0.03 mg increases the 
24-hour I-131 thyroid uptake over two times, not inducing long-term 
hyperthyreosis but only a slight excess of the upper limit of the 
reference range of fT4 levels (only in patients with subclinical 
hyperthyroidism).
In one of the first studies on the effects of rhTSH in healthy 
volunteers, the administration of 0.9 mg of thyrotropin resulted 
in a considerable increase in thyroid hormone levels, with a 61% 
increase in T4 and 81% increase in T3 levels [41]. In another study, 
an analogous dose of TSH was also administered in subjects with 
a healthy thyroid and the level of free hormones fT4 and fT3 in-
creased by 207% and 230%, respectively [42]. In both studies, 
the hormone release was induced after the value of TSH reached 
over 70–200 uIU/ml. Torres et al. were also one of the first to 
study the effect of rhTSH on the thyroid metabolic state of healthy 
volunteers in whom thyroid hormone levels increased nearly two 
times after the administration of 0.9 mg of rhTSH [38]. In this study, 
the authors suggested the use of lower doses of thyrotropin. After 
intramuscular administration of 0.1 mg of rhTSH, the level of T4 
increased by 54% and that of T3 grew by 89%. A dose of 0.3 mg 
caused T4 induction similar to that after the administration of 
0.9 mg; in the case of T3, the increase was even larger. This might 
suggest the existence of a threshold rhTSH dose; exceeding the 
dose does not result in larger induction of the production of free 
thyroid hormones. These studies on the response of a healthy 
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thyroid to the administration of rhTSH confirmed the necessity of 
seeking a new lower dose of rhTSH to be used in MNG radioactive 
iodine therapy. Romao et al. used an intramuscular dose of 0.1 mg 
of TSH and found the maximum level of TSH 24 hours after the 
administration of rhTSH (12 uIU/ml on average); the group treated 
included not only euthyroid patients, but also ones with subclini-
cal and overt hyperthyroidism [43]. Despite the use of antithyroid 
drugs, the increase was significantly higher in the patients with in-
creased baseline free hormone levels; consequently, the frequency 
of adverse effects typical of overt hyperthyroidism was higher in 
patients with overt hyperthyroidism at baseline (60.4%) than the 
euthyroid patients (17.8%). The authors also advise against using 
rhTSH in patients with subclinical hyperthyroidism in connection 
with a 31% frequency of side effects. In another paper, a dose 
of 0.2 mg was administered twice in euthyroid patients, resulting 
in temporary overt hyperthyroidism lasting 14 days, which is not 
desirable in elderly patients, particularly ones with concomitant 
circulatory disorders [25]. Consequently, the authors suggest rou-
tine preventive symptomatic treatment [25, 31, 44]. Studies with 
patients aged 42–80 years showed that a single dose of 0.1 mg 
of rhTSH induces hyperthyroidism, which increases the risk of 
left-sided diastolic heart failure three times [45]. In another group, 
a dose of 0.1 mg administered twice caused tachyarrhythmia in two 
patients [17]. In our patients, the administration of a single very low 
dose of 0.03 mg of rhTSH caused a 24% increase in free thyroxine 
levels in patients with subclinical hyperthyroidism at baseline and 
a 23% increase in those with MNG-EU. In the MNG-SC group, 
mean fT4 values only slightly exceeded the upper limit of the normal 
range at 48 hours after the administration of rhTSH and the first 
follow-up visit after the use of I-131 showed their normalization. The 
patients did not undergo antithyroid drug therapy before or after RIT. 
A dose of 0.03 mg of rhTSH seems to be safe both in patients who 
were in the euthyroid state at baseline and those with subclinical 
hyperthyroidism and the mean values of free hormones do not 
indicate the necessity for obligatory use of additional drugs in 
order to prevent possible side effects, as it was suggested in the 
papers cited. Additional administration of beta-blockers or other 
drugs having symptomatic effects, facilitating the treatment of hy-
perthyroidism, should be considered individually for each patient.
Many authors stress the necessity of exercising special cau-
tion during the use of rhTSH, not only due to the risk of adverse 
effects associated with hyperthyreosis, but also in connection with 
the possible occurrence of temporary goiter enlargement caused 
by the physiological effect of thyrotropin, which stimulates thyroid 
cells and increases their size, thus increasing the thyroid gland. 
Another factor influencing an increase in the size of the thyroid may 
be inflammation of the tissue occurring in some patients after the 
use of I-131, which may also cause temporary pain [17, 33, 46, 47]. 
Bonnema et al. studied 29 patients with goiters 99–440 ml in vol-
ume and found significantly more frequent side effects after the 
administration of 0.3 mg of rhTSH as compared with the control 
group; only two patients required the use of corticosteroids, which 
resulted in the expected improvement [31]. In another Italian center, 
all patients treated with rhTSH received obligatory steroids in order 
to avoid complications associated with temporary thyroid enlarge-
ment [17, 26]. Other authors also described cases of a temporary 
increase in goiter volume, occurring in as many as 24% of the pa-
tients treated with a neoadjuvant dose of 0.3 mg of thyrotropin [35]. 
The volume of the goiter at 24 hours after the injection increased 
by approx. 10%, at 48 hours by 24% and returned to the normal 
size after 7 days in 9 out of 10 followed-up patients. In the case 
of a dose of rhTSH equal to or lower than 0.03 mg, no statistically 
significant cases of goiter enlargement were found.
Conclusions
A single intramuscular injection of a very low dose (0.03 mg) 
of recombinant human thyrotropin considerably increases the 
degree and homogeneity of RAIU in large multi-nodular goiter, 
both euthyroid and subclinically hyperthyroid. The administration 
of rhTSH is well-tolerated and leads to similar outcomes in pa-
tients with subclinical hyperthyroidism and euthyroid individuals. 
Neoadjuvant administration of a low dose (0.03 mg) of rhTSH before 
I-131 seems to be an optimal method of management which may 
increase the effectiveness of RIT and decrease the exposure of the 
patients to absorbed doses of ionizing radiation. However, prior to 
recommending such administration, the effects of RIT should be 
thoroughly analyzed over at least one year of follow-up.
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